ter Heine R - Search Results

1

A pharmacokinetic and pharmacogenetic study of efavirenz in children: dosing guidelines can result in subtherapeutic concentrations.

ter Heine R, Scherpbier HJ, Crommentuyn KM, Bekker V, Beijnen JH, Kuijpers TW, Huitema AD. ter Heine R, et al. Antivir Ther. 2008;13(6):779-87. Antivir Ther. 2008. PMID: 18839779

2

Development and validation of a bioanalytical assay for the measurement of total and unbound teicoplanin in human serum.

Mouton JWA, Raaijmakers J, Botterblom M, Toonen M, Ter Heine R, Smeets RL, Brüggemann RJM, Te Brake L, Jager NGL. Mouton JWA, et al. Among authors: ter heine r. J Antimicrob Chemother. 2023 Nov 6;78(11):2723-2730. doi: 10.1093/jac/dkad290. J Antimicrob Chemother. 2023. PMID: 37757461 Free PMC article.

3

High-Dose Intermittent Treatment with the Multikinase Inhibitor Sunitinib Leads to High Intra-Tumor Drug Exposure in Patients with Advanced Solid Tumors.

Gerritse SL, Labots M, Ter Heine R, Dekker H, Poel D, Tauriello DVF, Nagtegaal ID, Van Den Hombergh E, Van Erp N, Verheul HMW. Gerritse SL, et al. Among authors: ter heine r. Cancers (Basel). 2022 Dec 9;14(24):6061. doi: 10.3390/cancers14246061. Cancers (Basel). 2022. PMID: 36551546 Free PMC article.

4

First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2.

Smit MJ, Sander AF, Ariaans MBPA, Fougeroux C, Heinzel C, Fendel R, Esen M, Kremsner PG, Ter Heine R, Wertheim HF, Idorn M, Paludan SR, Underwood AP, Binderup A, Ramirez S, Bukh J, Soegaard M, Erdogan SM, Gustavsson T, Clemmensen S, Theander TG, Salanti A, Hamborg M, de Jongh WA, McCall MBB, Nielsen MA, Mordmüller BG; COUGH-1 trial study group. Smit MJ, et al. Among authors: ter heine r. Lancet Microbe. 2023 Mar;4(3):e140-e148. doi: 10.1016/S2666-5247(22)00337-8. Epub 2023 Jan 18. Lancet Microbe. 2023. PMID: 36681093 Free PMC article. Clinical Trial.

5

Off-label, but on target: the evidence needed to implement alternative dosing regimens of anticancer drugs.

Overbeek JK, Ter Heine R, Verheul HMW, Chatelut E, Rudek MA, Gurney H, Plummer R, Gilbert DC, Buclin T, Burger DM, Bloemendal HJ, van Erp NP. Overbeek JK, et al. Among authors: ter heine r. ESMO Open. 2023 Feb;8(1):100749. doi: 10.1016/j.esmoop.2022.100749. Epub 2023 Jan 3. ESMO Open. 2023. PMID: 36603522 Free PMC article. No abstract available.

6

Evidence-based rationale for low dose nivolumab in critically ill patients with sepsis-induced immunosuppression.

van den Haak DAC, Otten LS, Koenen HJPM, Smeets RL, Piet B, Pickkers P, Kox M, Ter Heine R. van den Haak DAC, et al. Among authors: ter heine r. Clin Transl Sci. 2023 Jun;16(6):978-986. doi: 10.1111/cts.13503. Epub 2023 Mar 31. Clin Transl Sci. 2023. PMID: 37002646 Free PMC article.

7

Early Eculizumab Withdrawal in Patients With Atypical Hemolytic Uremic Syndrome in Native Kidneys Is Safe and Cost-Effective: Results of the CUREiHUS Study.

Bouwmeester RN, Duineveld C, Wijnsma KL, Bemelman FJ, van der Heijden JW, van Wijk JAE, Bouts AHM, van de Wetering J, Dorresteijn E, Berger SP, Gracchi V, van Zuilen AD, Keijzer-Veen MG, de Vries APJ, van Rooij RWG, Engels FAPT, Altena W, de Wildt R, van Kempen E, Adang EM, Ter Avest M, Ter Heine R, Volokhina EB, van den Heuvel LPWJ, Wetzels JFM, van de Kar NCAJ. Bouwmeester RN, et al. Among authors: ter heine r, ter avest m. Kidney Int Rep. 2022 Oct 18;8(1):91-102. doi: 10.1016/j.ekir.2022.10.013. eCollection 2023 Jan. Kidney Int Rep. 2022. PMID: 36644349 Free PMC article.

8

Dose optimalization of subcutaneous ravulizumab is predicted to yield significant savings and to improve patient friendliness.

Ter Avest M, Langemeijer SMC, Blijlevens NMA, van de Kar NCAJ, Ter Heine R. Ter Avest M, et al. Among authors: ter heine r. Br J Clin Pharmacol. 2023 Mar;89(3):1211-1215. doi: 10.1111/bcp.15602. Epub 2022 Dec 1. Br J Clin Pharmacol. 2023. PMID: 36394176 Free article.

9

What the Product Label Does Not Tell You About Drug-Drug Interaction Management: Time for a Re-Appraisal.

Burger DM, le Comte M, Smolders EJ, Jacobs TG, Ter Heine R, Knibbe CAJ, Pirmohamed M. Burger DM, et al. Among authors: ter heine r. J Clin Pharmacol. 2023 Nov;63(11):1181-1185. doi: 10.1002/jcph.2316. Epub 2023 Aug 1. J Clin Pharmacol. 2023. PMID: 37477172 No abstract available.

10

Incidence and risk factors for nevirapine-associated rash.

de Maat MM, ter Heine R, Mulder JW, Meenhorst PL, Mairuhu AT, van Gorp EC, Huitema AD, Beijnen JH. de Maat MM, et al. Among authors: ter heine r. Eur J Clin Pharmacol. 2003 Sep;59(5-6):457-62. doi: 10.1007/s00228-003-0613-3. Epub 2003 Aug 12. Eur J Clin Pharmacol. 2003. PMID: 12920493

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

162 results

Search Page